Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arteriosclerosis: later-stage trial registry
1 of 6 indexed Arteriosclerosis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Arteriosclerosis: 6 US clinical trials tracked, 1 recruiting.
Arteriosclerosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Nabi Biopharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition arteriosclerosis
OPEN 1 | RECR 17% | LATE 2 | EARLY 1 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Arteriosclerosis lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arteriosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arteriosclerosis is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Arteriosclerosis research.
Nabi Biopharmaceuticals accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Arteriosclerosis enrolment sits around 203 participants.
Median target enrolment is 203 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.
-
Arteriosclerosis research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Fundación EPIC
NCT07286578
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Merck Sharp & Dohme
NCT06008756
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Nabi Biopharmaceuticals
NCT00211939
Sapphire 3 CTO Study
OrbusNeich
NCT06358508
Distributed Registry
Stanford University
NCT03898570
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Indiana University
NCT02685098
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Arteriosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arteriosclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arteriosclerosis page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Arteriosclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nabi Biopharmaceuticals sponsors the most Arteriosclerosis trials on record, review their full trial history before evaluating a specific study. See Nabi Biopharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arteriosclerosis condition card totals 6 registered trials; most-linked intervention sevelamer; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.